Diabetes, Vol 49, Issue 3 476-484, Copyright © 2000 by American Diabetes Association

ARTICLES

Course of renal function in type 2 diabetic patients with abnormalities of albumin excretion rate

R Nosadini, M Velussi, E Brocco, M Bruseghin, C Abaterusso, A Saller, M Dalla Vestra, A Carraro, E Bortoloso, M Sambataro, I Barzon, F Frigato, B Muollo, M Chiesura-Corona, G Pacini, B Baggio, F Piarulli, A Sfriso and P Fioretto
Department of Endocrinology and Metabolic Diseases, University of Sassari, Italy.

Heterogeneity in renal structure has been described in type 2 diabetic patients with both microalbuminuria and proteinuria; in fact, only a subset of type 2 diabetic patients have the typical diabetic glomerulopathy. However, it is currently unknown whether abnormalities in albumin excretion rate (AER) have a different renal prognostic value depending on the underlying renal structure. Aims of this study were: 1) to study the course of renal function in type 2 diabetic patients with altered AER; 2) to evaluate the relationship between the course of glomerular filtration rate (GFR) and renal structure; and 3) to evaluate the relationship between the course of GFR and baseline AER levels, metabolic control, and blood pressure levels during a follow-up period of 4 years. A total of 108 type 2 diabetic patients, 74 with microalbuminuria (MA) and 34 with proteinuria (P), were recruited into a prospective study that encompassed: 1) a baseline kidney biopsy with morphometric measurements of glomerular parameters; 2) intensified antihypertensive treatment for an average 4-year period (blood pressure target <140/90 mmHg); and 3) determinations of GFR at baseline and every 6 months. Mean (+/- SD) GFR significantly decreased from baseline in both MA (-1.3+/-9.4 [95% CI -3.51 to +0.86], P < 0.05) and P (-3.0+/-13.0 ml x min(-1) x 1.73 m(-2) per year [-7.71 to +1.61], P < 0.01). However, the changes in GFR were quite heterogeneous. Thus, on the basis of percent GFR change per year from baseline (delta%GFR), both MA and P patients were defined as progressors or nonprogressors when they were below or above the median, respectively. Baseline parameters of glomerular structure had a strong influence on the course of GFR. Indeed, the odds ratios of being progressors significantly increased across the quartiles of baseline glomerular basement membrane (GBM) width and mesangial fractional volume [Vv(mes/glom)], being 2.71 and 2.85 higher, respectively, in the fourth quartile than in the first quartile (P < 0.01 for both). Conversely, nonprogressors outnumbered progressors in the first quartile of GBM width (odds ratio: 2.14, P < 0.05) and in the first quartile of Vv(mes/glom) (odds ratio: 2.28, P < 0.01). Baseline albumin excretion rate (AER) did not influence delta%GFR; in fact, the number of progressors did not increase across quartiles of baseline AER among either MA or P. Similarly, mean blood pressure levels during follow-up (and intensified antihypertensive therapy) did not affect the course of GFR: the number of progressors and nonprogressors did not change across quartiles of mean blood pressure. In contrast, HbA1c during follow-up had an impact on delta%GFR: the odds ratio for being a progressor increased across quartiles of HbA1c, particularly for the highest quartile (HbA1c >9.0%). In conclusion, the course of renal function is heterogeneous in type 2 diabetic patients with microalbuminuria or proteinuria. In fact, a subset of patients has a rapid decline in GFR over a 4-year follow-up period; these patients have more advanced diabetic glomerulopathy and worse metabolic control than the remaining patients, whose GFR remains stable. These two cohorts are otherwise undistinguishable as regards the degree of AER at baseline and tight blood pressure control. Kidney biopsy has an important prognostic role in these patients. Thus, tight blood pressure control, when not associated with satisfactory glycemic control, is unable to prevent rapid GFR decline in type 2 diabetic patients with typical diabetic glomerulopathy.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. Retnakaran, C. A. Cull, K. I. Thorne, A. I. Adler, R. R. Holman, and for the UKPDS Study Group Risk Factors for Renal Dysfunction in Type 2 Diabetes: U.K. Prospective Diabetes Study 74 Diabetes, June 1, 2006; 55(6): 1832 - 1839. [Abstract] [Full Text] [PDF]

				F. C. Sasso, L. De Nicola, O. Carbonara, R. Nasti, R. Minutolo, T. Salvatore, G. Conte, R. Torella, and for the NID-2 (Nephropathy in Diabetes-Type 2) Stu Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care, March 1, 2006; 29(3): 498 - 503. [Abstract] [Full Text] [PDF]

				M. L. Caramori, P. Fioretto, and M. Mauer Enhancing the Predictive Value of Urinary Albumin for Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2006; 17(2): 339 - 352. [Abstract] [Full Text] [PDF]

				R. Nosadini, M. Velussi, E. Brocco, C. Abaterusso, A. Carraro, F. Piarulli, G. Morgia, A. Satta, R. Faedda, A. Abhyankar, et al. Increased Renal Arterial Resistance Predicts the Course of Renal Function in Type 2 Diabetes With Microalbuminuria Diabetes, January 1, 2006; 55(1): 234 - 239. [Abstract] [Full Text] [PDF]

				K. V. Lemley, D. B. Boothroyd, K. L. Blouch, R. G. Nelson, L. I. Jones, R. A. Olshen, and B. D. Myers Modeling GFR trajectories in diabetic nephropathy Am J Physiol Renal Physiol, October 1, 2005; 289(4): F863 - F870. [Abstract] [Full Text] [PDF]

				K.-H. Song, S. H. Ko, H.-W. Kim, Y.-B. Ahn, J.-M. Lee, H.-S. Son, K.-H. Yoon, B.-Y. Cha, K.-W. Lee, and H.-Y. Son Prospective Study of Lipoprotein(a) as a Risk Factor for Deteriorating Renal Function in Type 2 Diabetic Patients With Overt Proteinuria Diabetes Care, July 1, 2005; 28(7): 1718 - 1723. [Abstract] [Full Text] [PDF]

				M. Dalla Vestra, M. Mussap, P. Gallina, M. Bruseghin, A. M. Cernigoi, A. Saller, M. Plebani, and P. Fioretto Acute-Phase Markers of Inflammation and Glomerular Structure in Patients with Type 2 Diabetes J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S78 - S82. [Abstract] [Full Text] [PDF]

				J. L. Gross, M. J. de Azevedo, S. P. Silveiro, L. H. Canani, M. L. Caramori, and T. Zelmanovitz Diabetic Nephropathy: Diagnosis, Prevention, and Treatment Diabetes Care, January 1, 2005; 28(1): 164 - 176. [Abstract] [Full Text] [PDF]

				R. Nosadini, M. Velussi, E. Brocco, C. Abaterusso, F. Piarulli, G. Morgia, A. Satta, R. Faedda, A. Abhyankar, H. Luthman, et al. Altered Transcapillary Escape of Albumin and Microalbuminuria Reflects Two Different Pathogenetic Mechanisms Diabetes, January 1, 2005; 54(1): 228 - 233. [Abstract] [Full Text] [PDF]

				R. J. MacIsaac, C. Tsalamandris, S. Panagiotopoulos, T. J. Smith, K. J. McNeil, and G. Jerums Nonalbuminuric Renal Insufficiency in Type 2 Diabetes Diabetes Care, January 1, 2004; 27(1): 195 - 200. [Abstract] [Full Text] [PDF]

				R. Nosadini and G. Tonolo Relationship between Blood Glucose Control, Pathogenesis and Progression of Diabetic Nephropathy J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S1 - 5. [Abstract] [Full Text]

				L. E. Boulware, B. G. Jaar, M. E. Tarver-Carr, F. L. Brancati, and N. R. Powe Screening for Proteinuria in US Adults: A Cost-effectiveness Analysis JAMA, December 17, 2003; 290(23): 3101 - 3114. [Abstract] [Full Text] [PDF]

				M. A. C. Onuigbo Causes of Renal Failure in Patients With Type 2 Diabetes Mellitus JAMA, October 8, 2003; 290(14): 1855 - 1855. [Full Text] [PDF]

				H. Kramer and C.-y. Hsu Causes of Renal Failure in Patients With Type 2 Diabetes Mellitus--Reply JAMA, October 8, 2003; 290(14): 1855 - 1856. [Full Text] [PDF]

				S. De Cosmo, R. Trevisan, M. Dalla Vestra, M. Vedovato, A. Argiolas, A. Solini, A. Saller, F. Damone, A. Tiengo, V. Trischitta, et al. PC-1 Amino Acid Variant Q121 Is Associated With a Lower Glomerular Filtration Rate in Type 2 Diabetic Patients With Abnormal Albumin Excretion Rates Diabetes Care, October 1, 2003; 26(10): 2898 - 2902. [Abstract] [Full Text] [PDF]

				G. Bruno, F. Merletti, A. Biggeri, G. Bargero, S. Ferrero, G. Pagano, and P. C. Perin Progression to Overt Nephropathy in Type 2 Diabetes: The Casale Monferrato Study Diabetes Care, July 1, 2003; 26(7): 2150 - 2155. [Abstract] [Full Text] [PDF]

				G. Wolf and E. Ritz Diabetic Nephropathy in Type 2 Diabetes Prevention and Patient Management J. Am. Soc. Nephrol., May 1, 2003; 14(5): 1396 - 1405. [Full Text] [PDF]

				M. Dalla Vestra, A. Masiero, A. M. Roiter, A. Saller, G. Crepaldi, and P. Fioretto Is Podocyte Injury Relevant in Diabetic Nephropathy?: Studies in Patients With Type 2 Diabetes Diabetes, April 1, 2003; 52(4): 1031 - 1035. [Abstract] [Full Text] [PDF]

				A. Solini, M. Dalla Vestra, A. Saller, R. Nosadini, G. Crepaldi, and P. Fioretto The Angiotensin-Converting Enzyme DD Genotype Is Associated With Glomerulopathy Lesions in Type 2 Diabetes Diabetes, January 1, 2002; 51(1): 251 - 255. [Abstract] [Full Text] [PDF]

				P. K. Christensen, S. Larsen, T. Horn, S. Olsen, and H.-H. Parving Renal function and structure in albuminuric type 2 diabetic patients without retinopathy Nephrol. Dial. Transplant., December 1, 2001; 16(12): 2337 - 2347. [Abstract] [Full Text] [PDF]

				M. P. Cohen, G. T. Lautenslager, and C. W. Shearman Increased Collagen IV Excretion in Diabetes: A marker of compromised filtration function Diabetes Care, May 1, 2001; 24(5): 914 - 918. [Abstract] [Full Text]